Agilent Technologies Inc. Stock
Agilent Technologies Inc. gained 0.160% compared to yesterday.
Our community is currently high on Agilent Technologies Inc. with 5 Buy predictions and 1 Sell predictions.
So far the community has only identified positive things for Agilent Technologies Inc. stock. The most positive votes were given for criterium "EBIT Margin".
Pros and Cons of Agilent Technologies Inc. in the next few years
Pros
1
Higher EBIT margin than peer group
1
Market Leader or Top 3
1
Known brand
Cons
0
-
Performance of Agilent Technologies Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agilent Technologies Inc. | 0.160% | 2.977% | 13.076% | 56.095% | 28.735% | 126.652% | 199.512% |
| Hologic Inc. | -0.300% | 4.117% | 4.645% | 8.984% | -6.748% | 56.099% | 75.919% |
| Waters Corp. | -0.690% | 2.837% | 13.281% | 69.591% | 43.564% | 70.368% | 144.149% |
| Cerner Corp. | -1.390% | 0.060% | 4.054% | 4.679% | 3.388% | 27.126% | 35.115% |
Comments
Other discussions about Agilent Technologies Inc. Stock
Trading Agilent Technologies Inc.
Trading Agilent Technologies Inc.
News
Agilent Completes the InfinityLab Bio LC Portfolio
Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the
Agilent Presents Thought Leader Award to Dr. Stéphane Bayen
Agilent Technologies Inc. (NYSE: A) today announced that Stéphane Bayen has received an Agilent Thought Leader Award. Dr. Bayen is an Associate Professor in the Department of Food Science and
Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer
Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO)